## **Peer Review File**

Article Information: <a href="https://dx.doi.org/10.21037/tp-23-351">https://dx.doi.org/10.21037/tp-23-351</a>

## Reviewer A

The editorial commentary by Velasco-Hernandez and Menédez gives a comprehensive overview over lncRNAs used as a means of stratifying adult AML patients using previously published literature and the newly added lncRNA subset to identify high and low risk pediatric AML recently published in JCO. I only have a minor correction:

Page 1 Line: "can be originated by" – not grammatically correct, should be changed to something like "can originate from..."

**Reply to reviewer A:** We thank the reviewer for the detailed reading of the manuscript. We have accordingly modified this sentence.

Changes in the text: Page 1, line 29

## Reviewer B

The authors comment the utility of long non-coding RNA (lncRNA) signature to clarify patients with pediatric AML into risk category subgroups.

Although IncRCA would provide additional information to risk groups at diagnosis, risk stratification should be done carefully especially for determining patients in need of hematopoietic stem cell transplantation. The authors should refer to comments by Z.R. McCaw et al (J Clin Oncol 10.1200/JCO.23.00465).

**Reply to reviewer B:** We appreciate reviewer comment and we have now modified the manuscript according to his/her suggestions.

Changes in the text: Page 2, Lines 89-91

Minor points: "event-free" should be "event-free survival" in line 66.

**Reply to reviewer B:** We have included the missing word.

Changes in the text: Page 2, line 66